RealTime Dynamix™: Inflammatory Bowel Disease US Q3 2017 Spotlight

Remicade is considered by many as the go-to agent for treating IBD (Crohn’s disease and Ulcerative Colitis), but the introduction and adoption of TNF-inhibiting biosimilars is starting to shake up the IBD biologics market, according to RealTime Dynamix™: Inflammatory Bowel Disease US Q3, a survey of 103 US gastroenterologists fielded in August 2017.

Click the button below to view highlights from this report:

Download Report Spotlight

2017-10-17T19:42:24+00:00